托吡卡胺对映体的毛细管电泳-方波安培分离检测

采用毛细管电泳-方波安培检测法,在熔融石英毛细管(75 μm i.d.×50 cm)中,以7 mmol/L 三羟甲基氨基甲烷(Tris)-10 mmol/L柠檬酸-2 mmol/L硼酸-15mmol/L β-环糊精 （β-CD） (pH 3.0)为电泳介质,采用重力进样,高度差为20 cm,进样时间为10 s,在分离电压为15 kV,方波平衡电位+0.8 V的条件下,实现了托吡卡胺对映体的分离检测。线性范围为5~750 μmol/L,检出限为2 μmol/L。对影响分离度的因素β-CD浓度、硼酸浓度及p     

CE法测定CD45-FITC荧光抗体溶液中的游离FITC

建立了测定CD45-FITC荧光抗体样品溶液中游离FITC浓度的毛细管电泳(CE)方法。熔融石英毛细管45 cm(有效长度30 cm)×75μm i.d.;0.05 mol·L-1磷酸氢二钠-磷酸二氢钠缓冲液(含5g·L-1PEG4000,p H=7.14);分离电压+12 k V;进样压力0.5 psi(3.45 k Pa),进样时间3.0 s;分离温度25℃;UV-Vis检测器检测波长200 nm。该方法能有效测定CD45-FITC荧光抗体样品溶液中游离的FITC含量,线性回归方程相关系数r=0.9900,检测限LOQ=0.20μg·m L-1。样品加标回收率为105.49%,相对标准偏差小于5.36%。该方法快速、灵敏、重现性好,能用于CD45-FITC荧光抗体样品溶液中游离FITC的快速测定。     

在柱双重富集毛细管电泳法测定卷烟样品中的无机阴离子

采用在柱阴离子选择性耗尽进样(ASEI)-碱堆积(BS)双重富集毛细管电泳法测定了卷烟样品中无机阴离子。毛细管先充满含0.4 mmol/L十四烷基三甲基溴化铵(TTAB)的三羟甲基氨基甲烷(Tris)缓冲液抑制电渗流;再以高差法引入水塞,吸附于毛细管壁的TTAB溶解到水中,使该段毛细管的zeta电势变负;电泳电源用负高压,电动进样时样品池中阴离子快速迁移并堆积在毛细管内缓冲液和水塞界面上,同时流向进样端的电渗流将水塞排出毛细管;接着电动注入NaOH溶液,快速迁移的OH-与来自缓冲液的Tris+形成低电导样品区,可进一步堆积样品带,还可使电动进样的时间延长。同常规电动进样相比,该双重富集法可达到(0.8~1.3)×105的富集倍数。用本方法测定了卷烟中6种无机阴离子,检出限低于6.2 ng/L。     

柱前衍生化-非水毛细管电泳法高效分离饮料中的脂肪醛

以9,10-菲醌作为柱前衍生试剂,采用非水毛细管电泳模式考察并优化了脂肪醛的分离条件。实验采用毛细管(总长58.5 cm,有效长度50 cm,内径50 μm),应用80 mmol/L NH4Ac、1.4 mol/L HAc缓冲体系,于20 ℃、5 kPa(50 mbar)下压力进样 8 s,在不加入其他添加剂的情况下,实现了7种脂肪醛的高效基线分离,检出限为0.37～0.87 μmol/L,线性范围为0.78～25 μmol/L。应用所建立的方法对实际样品进行了测定,结果令人满意。     

高效毛细管电泳前沿分析法研究酸性药物那格列奈与人血浆白蛋白的结合

用高效毛细管电泳前沿分析法研究了酸性药物那格列奈与人血浆白蛋白的结合常数、结合位点和结合率。使用未涂层的毛细管柱 (4 0cm× 5 0 μmi.d .;有效柱长 32cm) ,磷酸盐缓冲溶液 (pH 7.4 ,离子强度0 .17)为背景溶液 ,在紫外检测波长 2 14nm、运行电压 18kV和重力进样 10 0s的条件下 ,利用那格列奈谱峰的平台高度和游离药物浓度的良好线性关系 (r>0 .999,n =6 ) ,测定了那格列奈的游离药物浓度。固定药物浓度 (2 0 0 μmol L ,2 5 0 μmol L) ,考察不同的蛋白质浓度对结合的影响 ;固定蛋白质浓度 (10 0 μmol L) ,考察不同的药物浓度对结合的影响。实验数据采用非线性拟和程序进行处理 ,得到了那格列奈的蛋白质结合参数。高效毛细管电泳前沿分析法测定的数据重现性良好 (RSD <2 .5 % ,n =3) ,在药代动力学和药效学研究方面具有简便、准确的优点。     

手性冠醚为手性分离选择剂的胶束毛细管电泳在线富集分离吉米沙星对映体

以手性冠醚为胶束毛细管电泳手性分离选择剂,对吉米沙星对映体药物的在线富集分离进行了研究.考察了阳离子表面活性剂十二烷基三甲基溴化铵浓度、运行缓冲溶液中有机添加剂含量和进样方式对对映体的富集和分离度的影响.使用未涂层毛细管柱(37 cm×51 μm,有效柱长30 cm),45 mmol/L Bis-Tris缓冲液+10 mmol/L十二烷基三甲基溴化铵(DTAB)+1 mmol/L手性冠醚+11%乙腈为运行缓冲溶液(pH=4.0),在紫外检测波长280 nm、运行电压-10 kV、电动进样条件下,对吉米沙星对映体进行在线推扫(sweeping)富集分离,在基线分离的前提下,富集倍数可达600～700倍.吉米沙星浓度为0.3 μmol/L时,两对映体峰高的相对标准偏差<4.0%(n=7).本方法为毛细管电泳在痕量对映体药物分析等方面的应用提供了新方法.     

酮洛芬与蛋白结合作用的高效液相色谱-迎头分析法研究及其与高效毛细管电泳-迎头分析法的比较

采用高效液相色谱-迎头分析法(HPLC-FA),以67 mmol/L (pH 7.4, I=0.17 mol/L) 的等渗磷酸盐缓冲液为流动相,Pinkerton GFF　Ⅱ-S5-80内表面反相柱(150 mm×4.6 mm i.d., 5 μm)为固定相,254 nm下检测,研究了酮洛芬与人血清白蛋白(HSA)的结合作用,通过非线性回归参数估算求得酮洛芬与HSA的结合参数。与高效毛细管电泳-迎头分析法(HPCE-FA)相比,HPLC-FA法具有高灵敏度的优势,但进样量较大,分析时间较长。HPLC-F     

毛细管区带电泳法测定板蓝根注射液中四种核苷的含量

采用毛细管区带电泳法测定了板蓝根注射液中胞苷、腺苷、鸟苷和尿苷的含量。电泳条件:采用未涂层石英毛细管(32.5 cm×50 μm i.d.,有效长度23.5 cm),以60 mmol/L硼砂溶液-10%(体积分数)异丙醇-20%（体积分数）乙腈为运行缓冲液,在25 ℃下以20 kV恒压电泳分离,压力进样 (1 kPa×10 s),检测波长254 nm。对电泳条件各因素进行了讨论,如缓冲液的种类、浓度和pH值,有机改性剂的种类和浓度,分离电压和毛细管温度等。样品经0.45 μm微孔滤膜过滤后直接进样;采用外     

大体积进样-乙腈盐堆积-胶束扫集毛细管电动色谱法对马来酸氯苯那敏的测定

建立了大体积进样-乙腈盐堆积-胶束扫集毛细管电动色谱法测定马来酸氯苯那敏片中马来酸氯苯那敏的新方法,并考察了样品中乙腈和NaCl浓度对分离效果的影响.结果表明,以12 mmol/L四硼酸钠-50 mmol/L硼酸- 50 mmol/L十二烷基硫酸钠(SDS)为缓冲液(含10%甲醇,pH9.1),以70%乙腈- 200m...     

毛细管电泳电化学发光法分离检测西咪替丁

建立了以三联吡啶钌为发光体系的毛细管电泳电化学发光(CE-ECL)检测系统,并应用于分离和测定西咪替丁片剂中西咪替丁的含量。考察了检测电位,三联吡啶钌(Ru(bpy)32+)的溶液浓度,缓冲液的pH和溶液浓度,分离电压、进样电压与进样时间等因素对分离检测的影响。结果表明:在检测电位1.18V,Ru(bpy)32+溶液浓度为5 mmol/L,磷酸盐缓冲液(PBS)25 mmol/L(pH 7.8),进样时间10 s,进样电位10 kV,运行电位15 kV下,测得西咪替丁线性范围为2.8×10-6~4.0×10-4mol/L,检出限为1.2×10-7mol/L(S/N=3)。对1.0×10-5mol/L的西咪替丁标准溶液连续测定5次,电化学发光强度和迁移时间的RSD分别为3.9%和1.5%。方法已应用于西咪替丁片剂中西咪替丁含量的测定。     

Tudy on drug displacement interactions by capillary electrophoresis-frontal analysis

The interaction between 18-methyl norethindrone and ketoprofen, including the displacement of ketoprofen from human serum albumin binding sites, was investigated by the capillary electrophoresis-frontal analysis method (CE-FA) at room temperature. A very large sample plug was introduced hydrostatically into the capillary (65 cm × 50 μm i.d.; effective length of 35 cm) over 80 s at a height difference of 11 cm. The working conditions for CE-FA separation are as follows: operating voltage, 10 kV; running buffer, 67 mmol·L⁻¹ phosphate, pH 7.4. The unbound ketoprofen concentration was directly measured from the height of the frontal peak. When the concentration of 18-methyl norethindrone was increased from 0 to 200 μmol/L, the unbound ketoprofen concentration was found to increase from 22.4 to 26.4 μmol/L at 100 μmol/L total ketoprofen concentration and from 82.1 to 106.2 μmol/L at 200 μmol/L total ketoprofen concentration. From these data, it may be deduced that the administration of high concentration of 18-methyl norethindrone can displace ketoprofen from its secondary binding site. __________ Translated from Chinese Journal of Chromatography, 2005, 23(2)(in Chinese)     

Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis

A method of capillary electrophoresis frontal analysis (CEFA) is developed for the first time to study the binding of ketoprofen to human serum albumin (HSA) and compared with high-performance liquid chromatography frontal analysis (LCFA). The separation is performed in an uncoated fused-silica capillary (60-cm x 75- micro m i.d., 50-cm effective length) with a phosphate buffer (pH 7.4, ionic strength of 0.17M) as the running buffer. The applied voltage is 13 kV and the detection is set at 254 nm. A trapezoidal peak of the unbound ketoprofen appears after HSA elution in the electropherogram. The plateau height of the peak is employed to determine the unbound concentration of ketoprofen in the HSA equilibrated sample solution. The CEFA method provides the advantages of small sample injection volume and rapidity and the disadvantage of low sensitivity compared with LCFA. CEFA is applicable to the binding parameter estimation of ketoprofen to the secondary binding site; an association constant (K(2)) of 0.24 x 10(6)M(-1) and the number for the binding site per molecule HSA of 2.54 is estimated. In contrast, LCFA measures parameters for both primary and secondary sites, which are 1.05 x 10(6)M(-1) and 0.94 for K(1) and n(1), respectively, and 0.12 x 10(6)M(-1) and 3.16 for K(2) and n(2), respectively. It is found that ketoprofen binds mainly at the primary site at a molecular ratio of ketoprofen versus HSA lower than 0.75, and the binding at the secondary site occurs at a higher ratio.     

高效毛细管电泳法检测尿液中的假尿嘧啶核苷

假尿嘧啶核苷（ψ）主要来自ｔＲＮＡ的降解,已证实在癌症患者尿液中排泄量异常,可以作为肿瘤诊断的极有用的标志物之一。用高效毛细管电泳法快速测定了人尿中的ψ,用涂层柱（２４ｃｍ×２５μｍｉ．ｄ．）及硼酸盐缓冲液,在线２００ｎｍ检测,可在４ｍｉｎ内使ψ与尿苷等及尿中其它内源物质完全分离。方法的日内、日间变异系数均小于４．０％,用磺基水杨酸作内标,以ψ浓度对相应的峰高或峰面积比定量得标准曲线（ｒ＞０．９９９０）,ψ最低检测限为４μｍｏｌ／Ｌ。     

人血清白蛋白与手性药物相互作用的毛细管电泳研究Ⅱ.药物对映体竞争结合参数的测定

 运用毛细管电泳（CE）技术,在对碱性药物Verapamil（VER）手性拆分的基础上对Verapamil与人血清白蛋白（HSA）平行体系进行了相互作用研究。通过定量HSA－VER体系中VER对映体的浓度,建立对映体对结合位点竞争的理论方程,获得了R和S型药物对映体与HSA的结合常数,其值分别为K（R）-VER=2．7×103×（±4．4×102）和K（S）-VER=8．5×102（±1.0×102）。实验证实,HSA具有手性选择性,与（R）－VER的结合强于与（S）-VER的结合,结合比随着HSA与（±）VER的浓度比而变化。     

Microchip capillary electrophoresis for frontal analysis of free bilirubin and study of its interaction with human serum albumin

To meet the need for bedside monitoring of free bilirubin for neonates under critical conditions, a microfluidic chip was fabricated and tested for its coupling with CE/frontal analysis (FA) to determine free bilirubin and study of its binding interaction with HSA, which regulated its concentration in plasma. The poly(methyl methacrylate) (PMMA) multichannel chip was fabricated by CO2 laser ablation and bonded with a fused-silica separation capillary for CE/FA separation with UV detection. The chip was designed to allow a complete assay of four electrophoretic runs using preconditioned channels to speed up the determination of free bilirubin and to deliver quick results for bedside monitoring. Under optimized conditions, the linear working range for free bilirubin was from 10 to 200 micromol with RSDs from 2.1 to 5.0% for n=3, and the LOD at 9 micromol for S/N=3. From a binding study between bilirubin and HSA under FA condition, the second binding constant for bilirubin-HSA was determined as 1.07x10(5) L/mol and the number of binding sites per HSA as 3.46. The results enabled the calculation of free bilirubin for jaundiced infants based on the clinically significant level of total bilirubin, producing a range of 118.3-119.4 micromol/L. The developed method is shown to meet the clinical requirement with additional margin of protection to detect the early rising level of free bilirubin prior to jaundice condition. The low-cost microchip CE/FA device is shown to produce quick results with high potential to deliver a suitable bed-side monitoring method for bilirubin management in neonates.     

高效迎头分析法测定药物-人血清白蛋白混合液中游离药物浓度

 用高效迎头分析法 (HPFA)测定了药物 人血清白蛋白 (HSA)混合液中游离药物的浓度。样品溶液不经任何处理直接进样到装有内表面反相固定相的色谱柱中 ,用 67mmol/L磷酸盐缓冲液 ( pH 7 4 ,I =0 17mol/L)作流动相。当进样体积足够大时 ,游离药物以平顶峰的形式被洗脱出来 ,平顶峰区域洗脱液中的药物浓度等于样品溶液中游离药物的浓度。收集平顶峰区域的洗脱液 ,然后将一定体积的洗脱液注入到反相色谱柱中 ,测定游离药物的浓度。用该法测定酮基布洛芬 HSA和头孢哌酮 HSA两种混合液中游离药物的浓度。     

毛细管电泳-迎头分析法测定血清或血浆中氯氮平的游离浓度

采用毛细管电泳-迎头分析模式体外实验测定了人血清白蛋白溶液、人血浆、兔血清和血浆样品溶液中游离氯氮平的浓度．根据前沿峰的峰高直接测定了样品溶液中的游离氯氮平浓度,并与传统超滤法进行了比较．通过考察施加的电压和运行缓冲液的组成对氯氮平电泳峰平台形成的影响确定了最优分离条件．讨论了氯氮平蛋白结合作用的选择性．     

Study of interaction between drug enantiomers and human serum albumin by flow injection-capillary electrophoresis frontal analysis

Flow injection (FI)-CE coupled with frontal analysis (FA) was applied to the study of stereoselectivity binding of amlodipine (AL) to HSA. Under protein-drug binding equilibrium, the unbound concentrations of drug enantiomers were measured by plateau height. The stereoselectivity of AL binding to HSA was proved by the different free fractions of two enantiomers. In physiological phosphate solution (pH 7.4, ionic strength 0.17) when 200 microM (+/-)AL was equilibrated with 300 microM HSA, the concentration of unbound R-AL was about 1.5 times higher than that of its antipode. The binding constants of two enantiomers, KR-AL and KS-AL, were 9910-11200 and 90200-104000 M(-1), respectively. The results obtained by the method were compared with those determined by conventional equilibrium dialysis (ED)-CE and fluorescence spectra. Hydroxypropyl-beta-CD (HP-beta-CD) (10 mM) was used as a chiral selector in pH 3.7 phosphate buffer. L-tryptophan (L-try) and ketoprofen (Ket) were used as displacement reagents to investigate the binding sites of AL to HSA. A binding synergism effect between hydrochlorothiazide (QL) and AL was observed and the results suggested that QL can destroy binding equilibrium of R-AL and S-AL toward HSA and they can occupy the same binding site of HSA (site I). The reproducibility was confirmed by RSD (RSD<1.5%) of the plateau height determined by FI-CE frontal analysis (FI-CE-FA). The FI-CE-FA was a good method to study protein-drug interaction.